文献速递造血干细胞移植与细胞治疗血栓与止血

TA-TMA与GVHD是内皮损伤的不同后果:MIDAS联盟研究

TA-TMA and GVHD are distinct consequences of endothelial injury: a MIDAS consortium study.
PubMed 文献 · Blood Adv · 2026-01-01

该前瞻性队列纳入368例成人异基因造血干细胞移植患者,移植前后检测内皮损伤生物标志物,发现移植后环磷酰胺显著降低急性GVHD发生率但不减少TA-TMA发生,且ST2等标志物可预测TA-TMA,提示两者风险因素和标志物谱不同。

要点

  • 移植后环磷酰胺降低急性GVHD但不减少TA-TMA。
  • 移植前肌酐升高与女性TA-TMA风险增加约40倍相关。
  • 第+28天ST2、sFLT-1和EGF与NRM和OS相关。

核心结论

  • TA-TMA与GVHD具有不同的风险因素和生物标志物谱,是内皮损伤的不同后果。

研究设计与样本

  • 前瞻性队列研究纳入368例成人(年龄≥18岁)首次异基因造血干细胞移植患者,移植前后检测内皮损伤生物标志物。

主要发现

  • 移植后环磷酰胺显著降低急性GVHD发生率,但对TA-TMA发生率无影响。
  • 严重TA-TMA可无急性GVHD发生,但高级别急性GVHD时更频繁。
  • 移植前血清肌酐和可检测的胎盘生长因子与移植后TA-TMA相关。
  • 性别分层多变量模型中,移植前肌酐每增加1 mg/dL,女性TA-TMA风险约40倍,男性约5倍。
  • 第+28天肌酐和ST2被识别为显著TA-TMA风险因素。

关键数值与推荐

  • 第+28天ST2、可溶性FLT-1和表皮生长因子与NRM和OS相关。
  • 基线或第+28天可溶性C5b-9与TA-TMA无关联。
  • 第+28天内皮激活和应激指数复合评分与严重TA-TMA、急性GVHD、NRM和OS显著相关。

临床怎么用

  • 监测移植前肌酐、移植前胎盘生长因子及第+28天ST2有助于识别TA-TMA高危成人患者。
  • 移植后环磷酰胺预防GVHD时仍需警惕TA-TMA发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) is a major risk factor for transplant-associated thrombotic microangiopathy (TA-TMA), and the 2 conditions often co-occur; therefore, we evaluated the biomarkers of endothelial injury to clarify their relationship. Our prospective Microangiopathy, Endothelial Damage in Adults Undergoing Stem Cell Transplantation cohort study of 368 adult (aged ≥18 years) patients measured biomarkers before and after their first allogeneic hematopoietic cell transplantation (HCT). We found that posttransplant cyclophosphamide significantly reduced acute GVHD incidence but had no impact on the reduction of TA-TMA incidence. Severe TA-TMA occurred in the absence of acute GVHD but also occurred more frequently with higher grades of acute GVHD. Pretransplant serum creatinine and detectable placental growth factor were associated with post-HCT TA-TMA. In sex-stratified multivariable models, a 1 mg/dL increase in pretransplant creatinine conferred a ∼40-fold higher TA-TMA risk in females vs approximately fivefold in males. Both landmark and association analyses identified day +28 creatinine and suppression of tumorigenicity 2 (ST2) as significant TA-TMA risk factors. Our study phenotyped TA-TMA and GVHD concurrently, and we show that ST2, previously linked to GVHD treatment response and nonrelapse mortality (NRM), also predicted TA-TMA. Day +28 levels of ST2, soluble FLT-1, and epidermal growth factor were associated with NRM and overall survival (OS), whereas baseline or day +28 soluble C5b-9 was not associated with TA-TMA. Post hoc analyses of Endothelial Activation and Stress Index composite score at day +28 after HCT found significant associations with severe TA-TMA, acute GVHD, NRM, and OS. Overall, our data highlight distinct risk factors and biomarker profiles for TA-TMA and GVHD and also identify differences between adults and reported biomarkers of TA-TMA in children.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Hahn T, Zhao Q, Miller EG, et al. TA-TMA and GVHD are distinct consequences of endothelial injury: a MIDAS consortium study. Blood Adv. 2026. PMID: 42234937. doi:10.1182/bloodadvances.2026019747

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。